Sucampo Pharmaceuticals, Inc. (SCMP) Tops Q2 EPS by 1c; Updates FY14 GAAP EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts SCMP Hot Sheet
Price: $18.00 --0%
Financial Fact:
Income (loss) before income taxes: 15.5M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Income (loss) before income taxes: 15.5M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) reported Q2 EPS of $0.04, $0.01 better than the analyst estimate of $0.03. Revenue for the quarter came in at $24.1 million versus the consensus estimate of $24.06 million.
Sucampo Pharmaceuticals, Inc. sees FY2014 EPS of $0.08-$0.13, versus the consensus of $0.18.
For earnings history and earnings-related data on Sucampo Pharmaceuticals, Inc. (SCMP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Booz Allen Hamilton falls despite earnings beat
- Goldman Sachs sees US stocks dip on tech earnings and macro shifts
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
